Separate and combined effects of scopolamine and mecamylamine on human event-related brain potentials

Human Psychopharmacology

Volumn 14, Issue 5, 1999, Pages 307-317

  Knott, Verner J ^a,b   Harr, Anne ^a   Ilivitsky, V ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b ROYAL OTTAWA HOSPITAL   (Canada)

Author keywords

Acetylcholine; Attention; Auditory and visual event related potentials; Continuous performance task; Information processing; Muscarinic receptors; Nicotinic receptors

Indexed keywords

MECAMYLAMINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; SCOPOLAMINE;

ADULT; ALERTNESS; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; EVENT RELATED POTENTIAL; HEARING; HUMAN; HUMAN EXPERIMENT; MALE; NEUROPHARMACOLOGY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REACTION TIME; REVIEW; VISION;

EID: 0032865948     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199907)14:5<307::AID-HUP101>3.0.CO;2-2     Document Type: Review

References (67)

1. Bajalan, A., Wright, C. and Vandervliet, V. (1986). Changes in the human visual evoked potential caused by the anticholinergic agent hyoscine hydrobromide: comparison with results in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 49, 175-182.
2. Beckman, H. and Moises, H. (1982). The cholinolytic biperden in depression: an acute placebo controlled study. Arch. Gen. Psychiat. Nevenkr., 231, 213-220.
3. 3H] nicotine binding sites in the human brain. J. Neurochem., 50, 1243-1247.
4. Bond, A. and Lader, M. (1974). The use of analogue scales in rating subjective feelings. Brit. J. Med. Psychol., 80, 1-46.
5. Brandeis, D., Naylor, H., Halliday, R., Callaway, E. and Yano, L. (1992). Scopolamine effects on visual information process, attention and event-related potential map latencies. Psychophysiology, 29, 315-336.
6. 3H] nicotine binding in human postmortem brain. J. Pharmacol. Exp. Therapeut., 282, 7-13.
7. Callaway, E. (1983). The pharmacology of information processing. Psychophysiology, 20, 359-370.
8. Callaway, E. (1984) Human information processing: some effects of methylphenidate, age and scopolamine. Biol. Psychiat. 19, 649-662.
9. Callaway, E., Halliday, R., Naylor, H. and Schechter, G. (1985). Effects of oral scopolamine on human stimulus evaluation. Psychopharmacology, 85, 133-138.
10. Dam, M. and London, E. (1983). Effects of cholinomimetics on glucose utilization in rat brain optic systems. Eur. J. Pharmacol., 87, 137-140.
11. Davies, P. (1979). Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Research, 171, 319-327.
12. Davies, P. and Muloney, A. (1976). Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet, 2, 1403.
13. de Toledo-Morrell, L., Evers, S., Hoeppner, T., Morrell, F., Garron, D. and Fox, J. (1991). A stress test for memory dysfunction: electrophysiologic manifestations of early Alzheimer's disease. Arch. Neurol., 48, 605-609.
14. Drachman, D. and Leavitt, J. (1974). Human memory and the cholinergic system Arch. Neurol., 30 113-121.
15. Dunne, M. (1985). An interpretation of some conflicting evidence regarding the effects of scopolamine upon vigilance. Psychopharmacology, 87 126.
16. Dunne, M. and Hartley E. (1985). the effects of scopolamine upon verbal memory: evidence for an attentional hypothesis. Acta Psychol., 58, 205-217.
17. Edwards, J., Wesnes, K., Warburton, D. and Gale, A. (1985). Evidence of a more rapid stimulus evaluation following cigarette smoking. Addit. Behav., 10, 113-126.
18. Eissenberg, T. (1996). Mecamylamine does not precipitate withdrawal in cigarette smokers. Psychopharmacology, 127, 328-336.
19. Fibiger, H. (1982). The organization and some projections of cholinergic neurons of the mammalian forebrain. Brain Res. Rev., 4, 327-388.
20. Gitelman, D. and Prohovnik, I. (1992). Muscarinic and nicotinic contributions to cognitive function and cortical blood flow. Neurobiol. of Aging, 13, 313-318.
21. Goodin, D., Squires, K. and Starr, A. (1978). Long latency event-related components of the auditory evoked potential in dementia. Brain, 101, 635-648.
22. Hammond, E., Meador, K., Aung-Din, R. and Wilder, B. (1987). Cholinergic modulation of human P3 event-related potentials. Neurol., 37, 346-349.
23. Houlihan, M., Pritchard, W. and Robinson, J. (1996a). Faster P300 latency after smoking in visual but not auditory oddball tasks. Psychopharmacology, 123, 231-238.
24. Houlihan, M., Pritchard, W. and Robinson, J. (1996b). The time course effects of smoking on stimulus evaluation and response selection. Psychophysiology, 10, 310-318.
25. Johnston, M., McKinney, M. and Coyle, J. (1981). Neocortical cholinergic innervation: a description of extrinsic and intrinsic components in the cat. Exptl. Brain Res., 43, 159-172.
26. Jones, G., Sahakian, B., Levy, R., Warburton, D. and Gray, J. (1992). Effects of acute sub-cutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology, 108, 485-497.
27. Kasper, S., Moises, H. and Beckman, H. (1981). The anticholinergic biperden in depressive disorders. Pharmacopsychiatry, 14, 195-198.
28. Katayama, S., Hirata, K., Tanaka, H., Yamazaki, K., Fujikane, M. and Ichimaru, Y. (1995). Efficacy of transdermal nicotine in dementia: a study using event-related potentials and a middle latency response. In Brain Imaging of Nicotine and Tobacco Smoking, Domino, F. (Ed.), NPP Books, Ann Arbor, pp. 289-302.
29. Knott, V. and Harr, A. (1996). Assessing the topographic EEG changes associated with aging and acute/long-term effects of smoking. Neuropsychobiology, 33, 210-222.
30. Knott, V., Harr, A. and Lusk-Mikkelsen, S. (1998). Functional utility of nicotine: arousal, mood and performance. In Nicotine, Caffeine and Social Drinking: Behaviour and Brain Function, Snel, J. and Lorist, M. (Eds), Harwood Academic, Amsterdam, pp. 115-130.
31. Knott, V., Kerr, C., Hooper, C. and Lusk-Mikkelsen, S. (1995). Cigarette smoking and event-related brain electrical potential (ERP) topographies associated with attentional-distractive processes. In Brain Imaging of Nicotine and Tobacco Smoking, Domino, E. (Ed.), NPP Books, Ann Arbor, pp. 191-221.
32. Kutas, M., McCarthy, G. and Donchin, E. (1977). Augmenting mental chronometry: the P300 as a measure of stimulus evaluation and time. Science, 197, 792-795.
33. Le Houezec, J., Halliday, R., Benowitz, N., Calloway, E., Naylor, H. and Herzig, K. (1994). A low dose of subcutaneous nicotine improves information processing in non-smokers. Psychopharmacology, 114, 628-634.
34. Levin, E. (1992). Nicotinic systems and cognitive function. Psychopharmacology, 108 417-431.
35. Levin, E., McGurk, S., South, D. and Butcher, L. (1989). Effects of combined muscarinic and nicotinic blockade on choice-array in the radical arm maze. Behav. Neural. Biol., 51, 270-277.
36. Levin, E., Rose, J., McGurk, S. and Butcher, L. (1990). Characterization of the cognitive effects of combined muscarinic and nicotinic blockade. Behav. Neural. Biol., 53, 103-113.
37. Little, J., Johnson, D., Minichiello, M., Weingartner, H. and Sunderland, T. (1998). Combined nicotinic and muscarinic blockade in elderly normal volunteers: cognitive, behavioural and physiological responses. Neuropsychopharmacology, 19, 60-69.
38. London, E., Dam, M. and Fanelli, R. (1988). Nicotine enhances cerebral glucose utilization in central components of the cat visual system. Brian Res. Bull., 20, 381-385.
39. Martin, B., Onaivi, E. and Martin, T. (1989). What is the nature of mecamylamine's antagonism of the central effects of nicotine? Biochem. Pharmacol., 38, 3391-3397.
40. McCulloh, H., Savaki, M., McCulloch, M. and Sokolof, L. (1980). Retina-dependent activation by apomorphine of metabolic activity in the superficial layer of the superior colliculus. Science, 207, 313-315.
41. Newhouse, P., Potter, A., Corwin, J. and Lennox, R. (1992). Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology, 108, 480-484.
42. Newhouse, P., Sunderland, T., Narang, P., Mellow, A., Lawlor, B. and Murphy, D. (1990). Neuroendocrine, physiologic and behavioral responses following intravenous nicotine in non-smoking healthy volunteers and patients with Alzheimer's disease. Psychoneuroendocrinology, 15, 471-484.
43. 11C-nicotine in brain of Alzheimer patients as visualized by position emission tomography. J. Neorol. Transm. (P-D sect), 2, 215-224.
44. Parkinson, D., Kratz, K. and Daw, N. (1988). Evidence for a nicotinic component to the actions of acetylcholine in cat visual cortex. Exp. Brain Res., 73, 553-568.
45. Perry, E., Perry, R., Blessed, G. and Tomlinson, B. (1976). Necropsy evidence of central cholinergic deficits in senile dementia. Lancet, 2, 143.
46. Perry, E., Gibson, P. Blessed G., Perry, R. and Tomlinson, B. (1977). Neurotransmitter enzyme abnormalities in senile dementia. J. Neurol. Sci., 34, 247-265.
47. Perry, E., Tomlinson, B., Blessed, G., Bergmann, K., Gibson, P. and Perry, R. (1978). Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J., 2, 1457-1459.
48. Picton, T. (1992). The P300 wave of the human event-related potential. J. Clin. Neurophysiol., 9, 456-479.
49. Pickworth, W., Herning, R. and Henningfield, J. (1988). Mecamylamine reduces some EEG effects of nicotine chewing gum in humans. Pharmacol. Biochem. Behav., 30, 149-153.
50. Pickworth, W., Fant, R., Butschky, M. and Henningfield, J. (1997). Effects of mecamylamine on spontaneous EEG and performance in smokers and nonsmokers. Pharmacol. Biochem. Behav., 56, 181-187.
51. Potter, D., Pickles, C., Roberts, R. and Rugg, M. (1992). The effects of scopolamine on event-related potentials in a continuous recognition memory task. Psychophysiology, 29, 29-37.
52. Riekkinen, P., Sirviö, J., Aultonen, M. and Riekkinen, P. (1990). Effects of concurrent manipulations of nicotinic and muscarinic receptors on spatial and passive avoidance learning. Pharmacol. Biochem. Behav., 37, 405-410.
53. Riekkinen, P., Koivisto, E., Sirviö, J. and Riekkinen, P. (1991). Joint modulation by neocortical electrical activity of nicotinic and muscarinic receptors. Brain Res. Bull., 27, 137-139.
54. Rossor, M., Garrett, N., Johnson, A., Mountjoy, C., Roth, M. and Iversen, L. (1982). A post-mortem study of the cholinergic and GABA systems in senile dementia. Brain, 105, 313-330.
55. Sahakian, B., Jones, G., Levy, R., Gray, J. and Warburton, D. (1989). The effects of nicotine on attention, information processing and short-term memory in patients with dementia of the Alzeimer type. Br. J. Psychiat, 154, 797-800.
56. Sannita, W., Maggi, L. and Rosadini, G. (1987) Effects of scopolamine (0-25-0-75 mg i.m.) on the quantitative EEG and the neoropsychological status of healthy volunteers. Neuropsychobiology, 17 199-205.
57. Sato, H., Hata, Y., Hagihara, K. and Tsumoto, T. (1987). A functional role of cholinergic innervation to neurons in the cat visual cortex. J. Neurophysiol., 58, 765-780.
58. Semlitsch, H., Anderer, P., Schuster, P. and Presslich, O. (1986). A solution for reliable and valid reduction of ocular artifacts applied to the P300 ERP. Psychophysiology, 23, 695-703.
59. Shaw, C., Needler, M. and Cynader, M. (1984). Oncogenesis of muscarinic acetylcholine binding sites in cat visual cortex: reversal of specific laminar distribution during the critical period. Dev. Brain Res., 14, 295-299.
60. Silito, A. and Kemp, J. (1983). Cholinergic modulation of the functional organization of the cat visual cortex. Brain Res., 289, 143-155.
61. Sunderland, T., Tariot, P., Cohen, R., Weingartner, H., Mueller, E. and Murphy, D. (1987). Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. Arch. Gen. Psychiat., 44, 418-426.
62. Sunderland, T., Tariot, P., Weingartner, H., Murphy, D., Newhouse, P., Mueller, E. and Cohen, R. (1986). Pharmacologic modelling of Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiat., 10, 599-610.
63. Warburton, D. and Rusted, J. (1993). Cholinergic control of cognitive resources. Neuropsychobiology, 28, 43-46.
64. Wenk, H., Volker, B. and Meyer, U. (1980). Cholinergic projections from magnocellular nuclei of the basal forebrain to cortical areas in cats. Brain Res. Revs., 2, 295-316.
65. Wesnes, K., Simpson, P. and Kidd, A. (1988). An investigation of the range of cognitive impairments induced by scopolamine 0-6 mg s.c. Hun. Psychopharmacol, 3, 27-41.
66. Whitehouse, P., Martino, A., Marcus, K., Zweig, R., Singer, H., Price, D. and Kellar, K. (1988). Reductions in acetylcholine and nicotine binding in several degenerative diseases. Arch. Neurol., 45, 722-724.
67. Wooley, D. (1976). Some aspects of the neurophysiological basis of insecticide action. Fed. Proc., 35, 2610-2617.